Early and delayed cardioprotective intervention with dexrazoxane each show different potential for prevention of chronic anthracycline cardiotoxicity in rabbits

Toxicology

Volumn 311, Issue 3, 2013, Pages 191-204

  Jirkovský, Eduard ^a   Lenčová Popelová, Olga ^a   Hroch, Miloš ^a   Adamcová, Michaela ^a   Mazurová, Yvona ^a   Vávrová, Jaroslava ^b   Mičuda, Stanislav ^a   Šimůnek, Tomáš ^c   Geršl, Vladimír ^a   Štěrba, Martin ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^c Charles University in Prague Faculty of Pharmacy   (Czech Republic)

Author keywords

Anthracycline; Cardioprotection; Cardiotoxicity; Dexrazoxane; Heart failure; Mechanisms

Indexed keywords

5 AMINOLEVULINATE SYNTHASE; ADENINE NUCLEOTIDE TRANSLOCASE; CITRATE SYNTHASE; DAUNORUBICIN; HEME OXYGENASE 1; MITOCHONDRIAL DNA; MITOCHONDRIAL PROTEIN; PEROXIREDOXIN 3; RAZOXANE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TRANSCRIPTION FACTOR NRF2; TROPONIN T;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASCITES; CARDIOTOXICITY; CAUSE OF DEATH; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; DOWN REGULATION; EARLY INTERVENTION; ECHOCARDIOGRAPHY; GENE EXPRESSION; HEART FUNCTION; HEART LEFT VENTRICLE FAILURE; HEART PROTECTION; HEME SYNTHESIS; HYDROTHORAX; MALE; MITOCHONDRIAL GENOME; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RABBIT; SYSTOLIC DYSFUNCTION; THERAPY DELAY; UPREGULATION; WEIGHT GAIN;

5-AMINOLEVULINATE SYNTHASE 1; ALAS1; ANT; ANTHRACYCLINE; BILIVERDIN REDUCTASE A; BVR A; CARDIOPROTECTION; CARDIOTOXICITY; COX1, COX4; DAU; DAUNORUBICIN; DEX; DEXRAZOXANE; FU; GSH; GSSG; HEART FAILURE; HEME OXYGENASE 1; HIF1Α; HO1; HYPOXIA-INDUCIBLE FACTOR 1Α; LEFT VENTRICULAR FRACTIONAL SHORTENING; LV FS; MALONDIALDEHYDE; MDA; MECHANISMS; MITOCHONDRIAL AND NUCLEAR GENOME-ENCODED COMPLEX IV SUBUNITS, RESPECTIVELY; MITOCHONDRIAL DNA; MITOCHONDRIAL SUPEROXIDE DISMUTASE; MITOCHONDRIAL TRANSCRIPTION FACTOR A.; MNSOD; MTDNA; NAD(P)H DEHYDROGENASE [QUINONE] 1; NADPH OXIDASES 2 AND 4; ND1; ND4 MITOCHONDRIAL GENOME-ENCODED COMPLEX I SUBUNITS; NDNA; NDUFS2; NOX2, NOX4; NQO1; NRF1; NRF2; NUCLEAR DNA; NUCLEAR FACTOR ERYTHROID 2-RELATED FACTOR 2; NUCLEAR GENOME-ENCODED COMPLEX I SUBUNIT; NUCLEAR RESPIRATORY FACTOR 1; OXIDIZED GLUTATHIONE; PEROXIREDOXIN 3; POST-TREATMENT FOLLOW UP; PRDX3; REDUCED GLUTATHIONE; TFAM;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CARDIOTONIC AGENTS; CITRATE (SI)-SYNTHASE; DAUNORUBICIN; HEART DISEASES; MALE; NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; RABBITS; RAZOXANE; TROPONIN T; VENTRICULAR FUNCTION, LEFT;

EID: 84881250804     PISSN: 0300483X     EISSN: 18793185     Source Type: Journal    
DOI: 10.1016/j.tox.2013.06.012     Document Type: Article

References (54)

1. Aapro M., Bernard-Marty C., Brain E.G., Batist G., Erdkamp F., Krzemieniecki K., Leonard R., Lluch A., Monfardini S., Ryberg M., Soubeyran P., Wedding U. Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper. Ann. Oncol. 2011, 22:257-267.
2. Adamcova M., Sterba M., Simunek T., Potacova A., Popelova O., Mazurova Y., Gersl V. Troponin as a marker of myocardiac damage in drug-induced cardiotoxicity. Expert Opin. Drug Saf. 2005, 4:457-472.
3. Barry E.V., Vrooman L.M., Dahlberg S.E., Neuberg D.S., Asselin B.L., Athale U.H., Clavell L.A., Larsen E.C., Moghrabi A., Samson Y., Schorin M.A., Cohen H.J., Lipshultz S.E., Sallan S.E., Silverman L.B. Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane. J. Clin. Oncol. 2008, 26:1106-1111.
4. Billingham M.E., Mason J.W., Bristow M.R., Daniels J.R. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat. Rep. 1978, 62:865-872.
5. Cvetkovic R.S., Scott L.J. Dexrazoxane: a review of its use for cardioprotection during anthracycline chemotherapy. Drugs 2005, 65:1005-1024.
6. De Sousa E., Veksler V., Minajeva A., Kaasik A., Mateo P., Mayoux E., Hoerter J., Bigard X., Serrurier B., Ventura-Clapier R. Subcellular creatine kinase alterations: implications in heart failure. Circ. Res. 1999, 85:68-76.
7. Dignam J.D., Martin P.L., Shastry B.S., Roeder R.G. Eukaryotic gene transcription with purified components. Methods Enzymol. 1983, 101:582-598.
8. Diop N.K., Vitellaro L.K., Arnold P., Shang M., Marusak R.A. Iron complexes of the cardioprotective agent dexrazoxane (ICRF-187) and its desmethyl derivative, ICRF-154: solid state structure, solution thermodynamics, and DNA cleavage activity. J. Inorg. Biochem. 2000, 78:209-216.
9. Dresdale A.R., Barr L.H., Bonow R.O., Mathisen D.J., Myers C.E., Schwartz D.E., d'Angelo T., Rosenberg S.A. Prospective randomized study of the role of N-acetyl cysteine in reversing doxorubicin-induced cardiomyopathy. Am. J. Clin. Oncol. 1982, 5:657-663.
10. Ewer M.S., Benjamin R.S. Doxorubicin cardiotoxicity: clinical aspects, recognition, monitoring. Cancer and the Heart 2006, 9-33. BC Decker Inc., Hamilton, ON. M.S. Ewer, E. Yeh (Eds.).
11. Ewer M.S., Ewer S.M. Cardiotoxicity of anticancer treatments: what the cardiologist needs to know. Nat. Rev. Cardiol. 2010, 7:564-575.
12. Ewer M.S., Speyer J.L. Chemical cardioprotetion against anthracycline cardiotoxicity. Cancer and the Heart 2006, 57-67. BC Decker Inc., Hamilton, ON. M.S. Ewer, E. Yeh (Eds.).
13. Gersl V., German J., Suba P., Mazurova Y., Hrdina R., Machackova J. IGF-I in experimental daunorubicin-induced cardiomyopathy in rabbits. Hum. Exp. Toxicol. 1999, 18:154-161.
14. Hasinoff B.B. Dexrazoxane (ICRF-187) protects cardiac myocytes against hypoxia-reoxygenation damage. Cardiovasc. Toxicol. 2002, 2:111-118.
15. Hasinoff B.B., Herman E.H. Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug?. Cardiovasc. Toxicol. 2007, 7:140-144.
16. Hasinoff B.B., Schroeder P.E., Patel D. The metabolites of the cardioprotective drug dexrazoxane do not protect myocytes from doxorubicin-induced cytotoxicity. Mol. Pharmacol. 2003, 64:670-678.
17. Hellmann K. Dexrazoxane-associated risk for secondary malignancies in pediatric Hodgkin's disease: a claim without evidence. J. Clin. Oncol. 2007, 25:4689-4690.
18. Hensley M.L., Hagerty K.L., Kewalramani T., Green D.M., Meropol N.J., Wasserman T.H., Cohen G.I., Emami B., Gradishar W.J., Mitchell R.B., Thigpen J.T., Trotti A., von Hoff D., Schuchter L.M. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J. Clin. Oncol. 2009, 27:127-145.
19. Herman E.H., Ferrans V.J. Preclinical animal models of cardiac protection from anthracycline-induced cardiotoxicity. Semin. Oncol. 1998, 25:15-21.
20. Herman E.H., Lipshultz S.E., Rifai N., Zhang J., Papoian T., Yu Z.X., Takeda K., Ferrans V.J. Use of cardiac troponin T levels as an indicator of doxorubicin-induced cardiotoxicity. Cancer Res. 1998, 58:195-197.
21. Jirkovsky E., Popelova O., Krivakova-Stankova P., Vavrova A., Hroch M., Haskova P., Brcakova-Dolezelova E., Micuda S., Adamcova M., Simunek T., Cervinkova Z., Gersl V., Sterba M. Chronic anthracycline cardiotoxicity: molecular and functional analysis with focus on nuclear factor erythroid 2-related factor 2 and mitochondrial biogenesis pathways. J. Pharmacol. Exp. Ther. 2012, 343:468-478.
22. Kand'ar R., Zakova P., Lotkova H., Kucera O., Cervinkova Z. Determination of reduced and oxidized glutathione in biological samples using liquid chromatography with fluorimetric detection. J. Pharm. Biomed. Anal. 2007, 43:1382-1387.
23. Lebrecht D., Geist A., Ketelsen U.P., Haberstroh J., Setzer B., Walker U.A. Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats. Br. J. Pharmacol. 2007, 151:771-778.
24. Lebrecht D., Setzer B., Ketelsen U.P., Haberstroh J., Walker U.A. Time-dependent and tissue-specific accumulation of mtDNA and respiratory chain defects in chronic doxorubicin cardiomyopathy. Circulation 2003, 108:2423-2429.
25. Legha S.S., Wang Y.M., Mackay B., Ewer M., Hortobagyi G.N., Benjamin R.S., Ali M.K. Clinical and pharmacologic investigation of the effects of alpha-tocopherol on adriamycin cardiotoxicity. Ann. N.Y. Acad. Sci. 1982, 393:411-418.
26. Lipshultz S.E., Lipsitz S.R., Orav E.J. Dexrazoxane-associated risk for secondary malignancies in pediatric Hodgkin's disease: a claim without compelling evidence. J. Clin. Oncol. 2007, 25:3179. author reply 3180.
27. Lyu Y.L., Kerrigan J.E., Lin C.P., Azarova A.M., Tsai Y.C., Ban Y., Liu L.F. Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Res. 2007, 67:8839-8846.
28. Martin E., Thougaard A.V., Grauslund M., Jensen P.B., Bjorkling F., Hasinoff B.B., Tjornelund J., Sehested M., Jensen L.H. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy. Toxicology 2009, 255:72-79.
29. Menna P., Paz O.G., Chello M., Covino E., Salvatorelli E., Minotti G. Anthracycline cardiotoxicity. Expert Opin. Drug Saf. 2012, 11(Suppl 1):S21-S36.
30. Myers C., Bonow R., Palmeri S., Jenkins J., Corden B., Locker G., Doroshow J., Epstein S. A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine. Semin. Oncol. 1983, 10:53-55.
31. O'Brien P.J., Dameron G.W., Beck M.L., Kang Y.J., Erickson B.K., Di Battista T.H., Miller K.E., Jackson K.N., Mittelstadt S. Cardiac troponin T is a sensitive, specific biomarker of cardiac injury in laboratory animals. Lab. Anim. Sci. 1997, 47:486-495.
32. Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001, 29:e45.
33. Pilz J., Meineke I., Gleiter C.H. Measurement of free and bound malondialdehyde in plasma by high-performance liquid chromatography as the 2,4-dinitrophenylhydrazine derivative. J. Chromatogr. B: Biomed. Sci. Appl. 2000, 742:315-325.
34. Popelova O., Sterba M., Haskova P., Simunek T., Hroch M., Guncova I., Nachtigal P., Adamcova M., Gersl V., Mazurova Y. Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death. Br. J. Cancer 2009, 101:792-802.
35. Sawyer D.B., Fukazawa R., Arstall M.A., Kelly R.A. Daunorubicin-induced apoptosis in rat cardiac myocytes is inhibited by dexrazoxane. Circ. Res. 1999, 84:257-265.
36. Simunek T., Klimtova I., Kaplanova J., Mazurova Y., Adamcova M., Sterba M., Hrdina R., Gersl V. Rabbit model for in vivo study of anthracycline-induced heart failure and for the evaluation of protective agents. Eur. J. Heart Fail. 2004, 6:377-387.
37. Spagnuolo R.D., Recalcati S., Tacchini L., Cairo G. Role of hypoxia-inducible factors in the dexrazoxane-mediated protection of cardiomyocytes from doxorubicin-induced toxicity. Br. J. Pharmacol. 2011, 163:299-312.
38. Sterba M., Popelova O., Lenco J., Fucikova A., Brcakova E., Mazurova Y., Jirkovsky E., Simunek T., Adamcova M., Micuda S., Stulik J., Gersl V. Proteomic insights into chronic anthracycline cardiotoxicity. J. Mol. Cell Cardiol. 2011, 50:849-862.
39. Sterba M., Popelova O., Vavrova A., Jirkovsky E., Kovarikova P., Gersl V., Simunek T. Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection. Antioxid. Redox Signal 2013, 18:899-929.
40. Suliman H.B., Carraway M.S., Ali A.S., Reynolds C.M., Welty-Wolf K.E., Piantadosi C.A. The CO/HO system reverses inhibition of mitochondrial biogenesis and prevents murine doxorubicin cardiomyopathy. J. Clin. Invest. 2007, 117:3730-3741.
41. Swain S.M., Vici P. The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review. J. Cancer Res. Clin. Oncol. 2004, 130:1-7.
42. Swain S.M., Whaley F.S., Gerber M.C., Ewer M.S., Bianchine J.R., Gams R.A. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J. Clin. Oncol. 1997, 15:1333-1340.
43. Swain S.M., Whaley F.S., Gerber M.C., Weisberg S., York M., Spicer D., Jones S.E., Wadler S., Desai A., Vogel C., Speyer J., Mittelman A., Reddy S., Pendergrass K., Velez-Garcia E., Ewer M.S., Bianchine J.R., Gams R.A. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J. Clin. Oncol. 1997, 15:1318-1332.
44. Tebbi C.K., London W.B., Friedman D., Villaluna D., De Alarcon P.A., Constine L.S., Mendenhall N.P., Sposto R., Chauvenet A., Schwartz C.L. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. J. Clin. Oncol. 2007, 25:493-500.
45. Thomas C., Vile G.F., Winterbourn C.C. The hydrolysis product of ICRF-187 promotes iron-catalysed hydroxyl radical production via the Fenton reaction. Biochem. Pharmacol. 1993, 45:1967-1972.
46. van Dalen E.C., Caron H.N., Dickinson H.O., Kremer L.C. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst. Rev. 2011, CD003917.
47. Van Vleet J.F., Ferrans V.J., Weirich W.E. Cardiac disease induced by chronic adriamycin administration in dogs and an evaluation of vitamin E and selenium as cardioprotectants. Am. J. Pathol. 1980, 99:13-42.
48. Wallace K.B. Doxorubicin-induced cardiac mitochondrionopathy. Pharmacol. Toxicol. 2003, 93:105-115.
49. Wallace K.B. Adriamycin-induced interference with cardiac mitochondrial calcium homeostasis. Cardiovasc. Toxicol. 2007, 7:101-107.
50. Ward J.D. A Manual for Laboratory Animal Management 2008, World Scientific Publishing Co. Pte. Ltd, Singapore.
51. Wojnowski L., Kulle B., Schirmer M., Schluter G., Schmidt A., Rosenberger A., Vonhof S., Bickeboller H., Toliat M.R., Suk E.K., Tzvetkov M., Kruger A., Seifert S., Kloess M., Hahn H., Loeffler M., Nurnberg P., Pfreundschuh M., Trumper L., Brockmoller J., Hasenfuss G. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation 2005, 112:3754-3762.
52. Yen H.C., Oberley T.D., Gairola C.G., Szweda L.I., St Clair D.K. Manganese superoxide dismutase protects mitochondrial complex I against adriamycin-induced cardiomyopathy in transgenic mice. Arch. Biochem. Biophys. 1999, 362:59-66.
53. Zhang S., Liu X., Bawa-Khalfe T., Lu L.S., Lyu Y.L., Liu L.F., Yeh E.T. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat. Med. 2012, 18:1639-1642.
54. Zhao Y., McLaughlin D., Robinson E., Harvey A.P., Hookham M.B., Shah A.M., McDermott B.J., Grieve D.J. Nox2 NADPH oxidase promotes pathologic cardiac remodeling associated with Doxorubicin chemotherapy. Cancer Res. 2010, 70:9287-9297.